Clinical relevance of the bile acid receptor TGR5 in metabolism

FS van Nierop, MJ Scheltema, HM Eggink… - The lancet Diabetes & …, 2017 - thelancet.com
The bile acid receptor TGR5 (also known as GPBAR1) is a promising target for the
development of pharmacological interventions in metabolic diseases, including type 2 diabetes, …

Irreversible electroporation (IRE): a narrative review of the development of IRE from the laboratory to a prostate cancer treatment

A Blazevski, MJ Scheltema, A Amin… - BJU …, 2020 - Wiley Online Library
Introduction Whilst whole‐gland radical treatment is highly effective for prostate cancer
control, it has significant impact on quality of life and is unnecessary ‘over‐treatment’ in many …

Guidelines of guidelines: focal therapy for prostate cancer, is it time for consensus?

S Ong, K Chen, J Grummet, J Yaxley… - BJU …, 2023 - Wiley Online Library
Objective To provide a summary and discussion of international guidelines, position statements
and consensus statements in relation to focal therapy (FT) for prostate cancer (PCa). …

[PDF][PDF] Wetgeving in de responsieve rechtsstaat

M Scheltema - RegelMaat 2018 (33), 2018 - bjutijdschriften.nl
De burger ervaart het vaak anders. De overheid ziet hij dan als bureaucratisch bol‐werk,
waarin ambtenaren zich achter de regels verschuilen. Juristen kunnen hem wel goed uitleggen …

Treatment outcomes from 68Ga-PSMA PET/CT–informed salvage radiation treatment in men with rising PSA after radical prostatectomy: prognostic value of a negative …

L Emmett, PJ van Leeuwen, R Nandurkar… - Journal of Nuclear …, 2017 - Soc Nuclear Med
68 Ga-PSMA (prostate-specific membrane antigen) PET/CT is increasingly used in men with
prostate-specific antigen (PSA) failure after radical prostatectomy (RP) to triage those who …

Patient selection for prostate focal therapy in the era of active surveillance: an International Delphi Consensus Project

KJ Tay, MJ Scheltema, HU Ahmed, E Barret… - Prostate cancer and …, 2017 - nature.com
Background: Whole-gland extirpation or irradiation is considered the gold standard for
curative oncological treatment for localized prostate cancer, but is often associated with sexual …

3-Year freedom from progression after 68Ga-PSMA PET/CT–triaged management in men with biochemical recurrence after radical prostatectomy: results of a …

L Emmett, R Tang, R Nandurkar, G Hruby… - Journal of Nuclear …, 2020 - Soc Nuclear Med
68 Ga-labeled prostate-specific membrane antigen (PSMA) PET/CT is increasingly used in
men with biochemical recurrence (BCR) after radical prostatectomy (RP), but its longer-term …

Focal irreversible electroporation as primary treatment for localized prostate cancer

W van den Bos, MJ Scheltema… - BJU …, 2018 - Wiley Online Library
Objectives To determine the safety, quality of life (QoL) and short‐term oncological outcomes
of primary focal irreversible electroporation ( IRE ) for the treatment of localized prostate …

Diagnostic accuracy of 68Ga‐prostate‐specific membrane antigen (PSMA) positron‐emission tomography (PET) and multiparametric (mp)MRI to detect intermediate‐grade intra …

MJ Scheltema, JI Chang, PD Stricker… - BJU …, 2019 - Wiley Online Library
Objective To evaluate the ability of prostate‐specific membrane antigen ( PSMA )‐positron‐emission
tomography ( PET )/computed tomography ( CT ) to detect intermediate‐grade intra‐…

Utilization of multiparametric prostate magnetic resonance imaging in clinical practice and focal therapy: report from a Delphi consensus project

MJ Scheltema, KJ Tay, AW Postema, DM De Bruin… - World journal of …, 2017 - Springer
Purpose To codify the use of multiparametric magnetic resonance imaging (mpMRI) for the
interrogation of prostate neoplasia (PCa) in clinical practice and focal therapy (FT). Methods …